OTCMKTS:ECTE

Echo Therapeutics Competitors

$0.02
-0.01 (-32.26 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.03
50-Day Range
$0.03
MA: $0.04
$0.05
52-Week Range
$0.00
Now: $0.02
$0.28
Volume67,111 shs
Average Volume74,197 shs
Market Capitalization$233,730.00
P/E RatioN/A
Dividend YieldN/A
Beta7.09

Competitors

Echo Therapeutics (OTCMKTS:ECTE) Vs. ARDMQ, IMRSQ, SCIE, ULGX, AKSY, and ESMC

Should you be buying ECTE stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Echo Therapeutics, including Aradigm (ARDMQ), IMRIS (IMRSQ), SpectraScience (SCIE), Urologix (ULGX), Aksys (AKSY), and Escalon Medical (ESMC).

Aradigm (OTCMKTS:ARDMQ) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Aradigm and Echo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AradigmN/AN/AN/AN/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Volatility & Risk

Aradigm has a beta of 2.91, indicating that its share price is 191% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, indicating that its share price is 609% more volatile than the S&P 500.

Profitability

This table compares Aradigm and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AradigmN/AN/AN/A
Echo TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Aradigm and Echo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aradigm0000N/A
Echo Therapeutics0000N/A

Summary

Echo Therapeutics beats Aradigm on 1 of the 1 factors compared between the two stocks.

IMRIS (OTCMKTS:IMRSQ) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Risk & Volatility

IMRIS has a beta of -10.69, meaning that its stock price is 1,169% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, meaning that its stock price is 609% more volatile than the S&P 500.

Profitability

This table compares IMRIS and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMRISN/AN/AN/A
Echo TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares IMRIS and Echo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMRISN/AN/AN/AN/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for IMRIS and Echo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMRIS0000N/A
Echo Therapeutics0000N/A

Summary

Echo Therapeutics beats IMRIS on 1 of the 1 factors compared between the two stocks.

Echo Therapeutics (OTCMKTS:ECTE) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Echo Therapeutics and SpectraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Echo TherapeuticsN/AN/AN/A
SpectraScienceN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Echo Therapeutics and SpectraScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Echo Therapeutics0000N/A
SpectraScience0000N/A

Volatility and Risk

Echo Therapeutics has a beta of 7.09, meaning that its share price is 609% more volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Valuation & Earnings

This table compares Echo Therapeutics and SpectraScience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Echo TherapeuticsN/AN/AN/AN/AN/A
SpectraScienceN/AN/AN/AN/AN/A

Summary

Echo Therapeutics beats SpectraScience on 1 of the 1 factors compared between the two stocks.

Urologix (OTCMKTS:ULGX) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Risk and Volatility

Urologix has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, meaning that its stock price is 609% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Urologix and Echo Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urologix0000N/A
Echo Therapeutics0000N/A

Valuation and Earnings

This table compares Urologix and Echo Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UrologixN/AN/AN/AN/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Urologix and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UrologixN/AN/AN/A
Echo TherapeuticsN/AN/AN/A

Summary

Echo Therapeutics beats Urologix on 1 of the 1 factors compared between the two stocks.

Aksys (OTCMKTS:AKSY) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares Aksys and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AksysN/AN/AN/A
Echo TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Aksys and Echo Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AksysN/AN/AN/AN/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Aksys and Echo Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aksys0000N/A
Echo Therapeutics0000N/A

Volatility & Risk

Aksys has a beta of -6.76, suggesting that its share price is 776% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, suggesting that its share price is 609% more volatile than the S&P 500.

Summary

Echo Therapeutics beats Aksys on 1 of the 1 factors compared between the two stocks.

Escalon Medical (OTCMKTS:ESMC) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Escalon Medical and Echo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Escalon Medical$9.40 millionN/A$-650,000.00N/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Echo Therapeutics has lower revenue, but higher earnings than Escalon Medical.

Volatility & Risk

Escalon Medical has a beta of -0.86, indicating that its stock price is 186% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, indicating that its stock price is 609% more volatile than the S&P 500.

Profitability

This table compares Escalon Medical and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Escalon Medical-15.54%-136.63%-26.09%
Echo TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Escalon Medical and Echo Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Escalon Medical0000N/A
Echo Therapeutics0000N/A

Summary

Echo Therapeutics beats Escalon Medical on 4 of the 5 factors compared between the two stocks.


Echo Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ARDMQ
Aradigm
0.0$0.05-0.0%$764,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01-0.0%$364,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00-0.0%$177,000.00N/A0.00
ULGX
Urologix
0.6$0.01-0.0%$113,000.00N/A0.00
AKSY
Aksys
0.0$0.00-0.0%$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.40-0.0%$0.00$9.40 million-6.67High Trading Volume
Increase in Short Interest
News Coverage
HRTT
Heart Tronics
0.0$0.02-0.0%$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00-0.0%$0.00N/A0.00
PECN
Photoelectron
0.2$0.03-0.0%$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25-0.2%$0.00$5.57 million0.00News Coverage
XCRP
Xcorporeal
0.0$0.00-0.0%$0.00N/A0.00
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.